四氢-4-(5-羟戊基)-(3AS,4S,6AR)-1H-噻吩并[3,4-D]咪唑-2(3H)-酮 | 53906-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并咪唑类化合物
• 中文名称: 四氢-4-(5-羟戊基)-(3AS,4S,6AR)-1H-噻吩并[3,4-D]咪唑-2(3H)-酮
• 英文名称: biotinol
• 英文别名: (3aS,4S,6aR)-4-(5-hydroxy-pentyl)tetrahydrothieno[3,4-d]imidazol-2-one；(3aS,4S,6aR)-4-(5-hydroxypentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one；(3aS,4S,6aR)-4-(5-hydroxypentyl)-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one
• CAS: 53906-36-8
• 化学式: C₁₀H₁₈N₂O₂S
• 分子量: 230.331
• InChiKey: RGIKRHKHRAAZIO-CIUDSAMLSA-N

物化性质

• 沸点：
  500.0±35.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)
• 溶解度：
  甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  86.7
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  四氢-4-(5-羟戊基)-(3AS,4S,6AR)-1H-噻吩并[3,4-D]咪唑-2(3H)-酮 在 吡啶 、 盐酸 、 sodium azide 、 copper(ll) sulfate pentahydrate 、 sodium ascorbate 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 (3aS,3a'S,4S,4'S,6aR,6a'R)-4,4'-(((((5-(1-(3-(((Z)-4-amino-2-fluorobut-2-en-1-yl)sulfonyl)benzyl)-1H-1,2,3-triazol-4-yl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(pentane-5,1-diyl))bis(tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one) hydrochloride
  参考文献：
  名称：

  [EN] BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF
  [FR] BIOSONDES POUR LYSYL OXYDASES ET LEURS UTILISATIONS

  摘要：

  本发明涉及能够结合特定胺氧化酶的新型生物探针。这些生物探针在检测和确定样本中特定胺氧化酶的浓度的方法中是有用的，同时也可用于定量评估特定胺氧化酶的抑制方法。

  公开号：

  WO2021155439A1
• 作为产物：
  描述：

  (+)生物素-N-琥珀酰亚胺基酯 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 为溶剂， 反应 4.0h， 以67%的产率得到四氢-4-(5-羟戊基)-(3AS,4S,6AR)-1H-噻吩并[3,4-D]咪唑-2(3H)-酮
  参考文献：
  名称：

  Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors

  摘要：

  The outstanding limitations to the oligopeptide as a therapeutic agent are poor oral availability and rapid biliary clearance. To address these concerns a series of eight peptidic HIV-1 protease inhibitors containing the structural segment of the vitamin biotin have been prepared. These have been evaluated with regard to the hypothesis that this vitamin would cloak the peptidic character of these oligopeptides, and thus impart to these inhibitors the potential for absorption and distribution via biotin transporters and receptors. By iterative optimization about a -Chal psi[CH- (OH)CH(OH)]Val- core inhibitory insert, three particularly potent inhibitors (K-i less than or equal to 10 nM) of the HIV-1 protease were obtained. Although excellent cell culture antiviral activity is observed for other peptidic protease inhibitors of comparable affinity, none in this series exhibited satisfactory antiviral activity. This failure is-attributed to the incompatibility of the hydrophilic and hydrogen-bonding biotin segment, with the facile membrane permeability and intracellular access presumably required for antiviral activity. The ability of the biotin to cloak the peptide, and thus render the overall appearance of the conjugate as that of a vitamin, was evaluated. Four of this series were evaluated for recognition by the Caco-2 cell intestinal biotin transporter, None inhibited competitively biotin uptake, indicating a lack of recognition. A vitamin may bind to a specific protein carrier, and thus attain an improved serum profile (by resistance to biliary clearance) and advantageous delivery to cells. Therefore, the serum concentrations of three were evaluated following an iv bolus in a rat model for serum clearance. One of the three protease inhibitors (L-idonamide, 6-cyclohexyl-2,5,6-trideoxy-2-(1-methylethyl)-5-[[3-methyl-1-oxo-2-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]butyl]amino]-N-[2-methyl-1-[[(2-pyridinylmethyl)amino] carbonyl]butyl]-, [3aS-[3a alpha,4 beta(1R*,2R*;3R*),6a alpha]]-) sustained a more than 5-fold increase in serum concentration at all time points relative to the benchmark structure. The remaining two had serum concentrations at least equal to the benchmark, suggestive of improved resistance to clearance. One(L-idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[[2-[[5-(hexahydro-2-oxo-1H-thieno-[3,4-d]imidazol-4-yl)pentyl]thio]benzoyl]amino]-2-(1-methylethyl)-N-[2-methyl-1-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]-, [3aS-[3a alpha,4 beta(1R*,2R*),6a alpha]]-) was prepared as a complex with the biotin-binding protein avidin. Avidin may resemble an endogenous serum biotin carrier protein. The antiviral activity (evaluated in an H9-HTLV(IIIB) acute HIV-1 infection assay) of the inhibitor and the avidin complex was identical. This suggests that the avidin-inhibitor complex is capable of cell internalization. Although the weak antiviral activity of these biotinylated inhibitors precludes consideration as practical HIV therapeutics, the overall data remain suggestive of vitamin cloaking of oligopeptides as a strategy of potential value.

  DOI：

  10.1021/jm00028a013

文献信息

• En Route to a Practical Primary Alcohol Deoxygenation
  作者：Xi-Jie Dai、Chao-Jun Li

  DOI：10.1021/jacs.6b02344

  日期：2016.4.27

  efficient mainly with activated alcohols, which dictates harsh reaction conditions and thus limits its synthetic utility. Later, a significant advancement has been made on aliphatic primary alcohol deoxygenation by employing a ruthenium complex, with good functional group tolerance and exclusive selectivity under practical reaction conditions. Its synthetic utility is further illustrated by excellent

  醇脱氧领域的一个长期科学挑战是在存在其他官能团（如广泛存在于生物分子中的游离羟基和胺）的情况下，具有高选择性和高效率的直接催化 sp(3) CO 去官能化。以前，选择性问题只能通过使用化学计量试剂的经典多步脱氧策略来解决。在此，我们提出了一种基于脱氢/沃尔夫-基什纳 (WK) 还原的催化后过渡金属催化氧化还原设计，以同时解决步骤经济性和选择性方面的挑战。我们假设的早期发展侧重于主要使用活化醇有效的铱催化过程，这决定了苛刻的反应条件，从而限制了其合成效用。之后，采用钌配合物在脂肪族伯醇脱氧方面取得了重大进展，在实际反应条件下具有良好的官能团耐受性和专属选择性。在简单和复杂的分子设置中，其卓越的效率以及完全的化学和区域选择性进一步说明了其合成效用。实验支持还包括机械讨论。总体而言，我们目前的方法成功地解决了相关领域中的上述挑战，为脂肪族伯醇的直接 sp(3) CO 去官能化提供了一种实用的基于
• Azoacetylenes for the Synthesis of Arylazotriazole Photoswitches
  作者：Patrick Pfaff、Felix Anderl、Moritz Fink、Moritz Balkenhohl、Erick M. Carreira

  DOI：10.1021/jacs.1c06014

  日期：2021.9.15

  TIPS-acetylene to aryldiazonium tetrafluoroborate salts gives a wide range of azoacetylenes, constituting an underexplored class of stable intermediates. In situ desilylation transiently leads to terminal arylazoacetylenes that undergo copper-catalyzed cycloadditions (CuAAC) with a diverse collection of organoazides. These include complex molecules derived from natural products or drugs, such as colchicine

  我们报告了一种针对新型芳基氮并三唑光开关及其光物理特性的模块化方法。锂化 TIPS-乙炔与芳基重氮四氟硼酸盐的加成得到范围广泛的偶氮乙炔，构成了一类尚未开发的稳定中间体。原位脱硅瞬时导致末端芳基偶氮乙炔发生铜催化环加成反应 (CuAAC)，并产生多种有机叠氮化物。这些包括源自天然产物或药物的复杂分子，例如秋水仙碱、紫杉醇、达菲和花生四烯酸。芳基氮并三唑显示近定量光异构化和长热Z-半条命。使用该方法，我们首次介绍了联乙炔平台的设计和合成。它允许实施连续和面向多样性的方法，将两种不同的偶联物连接到一个常见的光开关偶氮三唑中的独立可寻址乙炔。这在几种光开关偶联物的合成中得到了展示，具有作为 photoPROTAC 和生物素偶联物的潜在应用。
• 2-Azaadamantane<i>N</i>-oxyl (AZADO)/Cu Catalysis Enables Chemoselective Aerobic Oxidation of Alcohols Containing Electron-Rich Divalent Sulfur Functionalities
  作者：Yusuke Sasano、Naoki Kogure、Shota Nagasawa、Koki Kasabata、Yoshiharu Iwabuchi

  DOI：10.1021/acs.orglett.8b02528

  日期：2018.10.5

  The chemoselective oxidation of alcohols containing electron-rich sulfur functionalities (e.g., 1,3-dithianes and sulfides) into their corresponding carbonyl compounds with the sulfur groups can sometimes be a demanding task in modern organic chemistry. A reliable method for this transformation, which features azaadamantane-type nitroxyl radical/copper catalysis using ambient air as the terminal oxidant

  在现代有机化学中，有时将含有富电子功能的硫官能团（例如1,3-二硫醚和硫化物）的醇化学选择性氧化成其相应的具有硫基的羰基化合物，这可能是一项艰巨的任务。报道了这种转化的可靠方法，其特征在于使用环境空气作为末端氧化剂的氮杂金刚烷型硝基氧基自由基/铜催化。通过与各种常规醇氧化方法进行比较，证明了所开发方法的优越性。
• AVOIDANCE OF NON-SPECIFIC BINDING ON AN ACOUSTIC WAVE BIOSENSOR USING LINKER AND DILUENT MOLECULES FOR DEVICE SURFACE MODIFICATION
  申请人：THOMPSON Michael

  公开号：US20110306771A1

  公开（公告）日：2011-12-15

  An acoustic wave biosensor comprising a surface of a mixed self-assembling monolayer for receiving a probe-biomolecule is described herein. The biosensor surface may comprise a piezoelectric quartz crystal,—for detection purposes with the electromagnetic piezoelectric acoustic sensor (EMPAS)—upon which a mixed self-assembling monolayer is formed, which includes at least one linker, such as 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); its oligoethylene glycol (OEG) analog OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TU BTS). Linker/diluent systems for attaching a functionalizing entity to the surface of a biosensor are described, as well as methods for preparing a biosensor surface with an oligoethylene glycol linker.

  这里描述了一种声波生物传感器，包括用于接收探针生物分子的混合自组装单分子层的表面。生物传感器表面可能包括压电石英晶体，用于检测目的与电磁压电声传感器（EMPAS）一起使用，其上形成了混合自组装单分子层，其中包括至少一种连接剂，如2,2,2-三氟乙基-13-三氯硅基-十三酸酯（TTTA）；其寡乙二醇（OEG）类似物OEG化的TTTA（OEG-TTTA）；S-(2-(2-(2-(3-三氯硅基-丙氧基)-乙氧基)-乙氧基)-乙基)-苯基硫酸酯（OEG-TU BTS）。描述了用于将功能化实体连接到生物传感器表面的连接剂/稀释剂系统，以及使用寡乙二醇连接剂制备生物传感器表面的方法。
• [EN] SYNTHETIC RECEPTORS FOR IONOPHORIC COMPOUNDS<br/>[FR] RÉCEPTEURS SYNTHÉTIQUES POUR COMPOSÉS IONOPHORES
  申请人：UNIV GENT

  公开号：WO2019166475A1

  公开（公告）日：2019-09-06

  The present invention relates to synthetic receptors for ionophoric compounds, such as ionophoric toxins. Hence, the invention provides synthetic molecules capable of binding different ionophoric compounds, thereby being suitable for use in the detection, isolation and detoxification of such ionophoric compounds. The present invention further provides the use of such synthetic receptors in human and veterinary medicine, such as in the diagnosis, prevention and/or treatment of disorders caused by such ionophoric compounds. Finally, the invention provides methods of preparing such synthetic receptors for ionophoric compounds.

  本发明涉及用于离子载体化合物的合成受体，例如离子载体毒素。因此，本发明提供了能够结合不同离子载体化合物的合成分子，从而适用于检测、分离和解毒此类离子载体化合物。本发明还提供了在人类和兽医学中使用这种合成受体的方法，例如在诊断、预防和/或治疗由这类离子载体化合物引起的疾病。最后，本发明提供了制备此类离子载体化合物的合成受体的方法。